期刊
BLOOD REVIEWS
卷 24, 期 3, 页码 135-141出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2010.03.004
关键词
B-cell Chronic Lymphocytic Leukemia (CLL); Prognostic markers; 17p deletion
类别
资金
- Cancer Research UK Molecular Pathology of Cancer
- National Cancer Institute
- CLL Global Alliance
- NATIONAL CANCER INSTITUTE [P01CA081534] Funding Source: NIH RePORTER
CLL is extremely heterogeneous in its clinical course, with some patients living decades with no need for treatment whilst others have a rapidly aggressive clinical course. A major focus of research has been to try to identify those biological factors that influence this heterogeneity. The goal of therapy has been to maintain the best quality of life and treat only when patients become symptomatic from their disease. For the majority of patients this means following a watch and wait approach to determine the rate of progression of the disease and assess for development of symptoms. Any alteration to this approach will require identification of criteria that define patients sufficiently high-risk that they gain benefit by introduction of early therapy. use of molecular profiling to suggest particular therapies is currently appropriate only in defining the treatment of the minority of patients with 17p deletions or p53 mutations and in all other circumstances remains a clinical trial question. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据